Advertisement

Palivizumab

  • Giuseppe TridenteEmail author
Chapter

Abstract

Palivizumab (Synagis®, MedImmune, Abbott) is a recombinant humanized IgG1k monoclonal antibody (MEDI-493) directed to specific surface proteins of the respiratory syncytial virus (RSV).

Keywords

Congenital Heart Disease Respiratory Syncytial Virus Respiratory Syncytial Virus Infection Erythema Multiforme Congenital Heart Disease Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_31_MOESM1_ESM.xls (60 kb)
Supplementary material 1 (XLS 61 kb)

References

  1. 1.
    Palivizumab (Synagis®) BLA 971359 Clinical Review FDA June 1998Google Scholar
  2. 2.
    Palivizumab (Synagis®) WC500056731 Scientific Discussion EMEA, Oct 2004Google Scholar
  3. 3.
    Palivizumab (Synagis®) Product Information MedImmune, Apr 2012Google Scholar
  4. 4.
    Palivizumab (Synagis®) WC500056908 EPAR Annex I EMEA, Nov 2012Google Scholar
  5. 5.
    Navas L, Wang E, de Carvalho V et al (1992) Improved outcome of respiratory syncytial virus infection in high-risk hospitalized population of Canadian children. Pediatric Investigator Collaborative Network on Infections in Canada. J Pediatr 121:348–354PubMedCrossRefGoogle Scholar
  6. 6.
    IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102:531–537CrossRefGoogle Scholar
  7. 7.
    AAPC (1998) Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics 102:1211–1216CrossRefGoogle Scholar
  8. 8.
    Palivizumab (Synagis®) WC500131776 CHMP Assessment Report EMEA, Aug 2012Google Scholar
  9. 9.
    Turti TV, Baibarina EN, Degtiareva EA et al (2012) A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation. BMC Res Notes 5:484. doi: 10.1186/1756-0500-5-484 PubMedCrossRefGoogle Scholar
  10. 10.
    Cecchia PA, Nalysnyk L, Fernandes AW et al (2011) Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatr Crit Care Med 12:580–588CrossRefGoogle Scholar
  11. 11.
    Paes B, Mitchell I, Li A et al (2012) Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr 171:833–841PubMedCrossRefGoogle Scholar
  12. 12.
    Mori M, Kawashima H, Nakamura H et al (2011) Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. J Infect Chemother 17:254–263PubMedCrossRefGoogle Scholar
  13. 13.
    Taylor RS (2012) CARESS The Canadian registry of palivizumab. Pediatr Infect Dis J 31:212–213PubMedCrossRefGoogle Scholar
  14. 14.
    Carbonell-Estrany X (2003) Palivizumab outcomes registry data from Spain: infección respiratoria infantile por virus respiratorio sincitial (IRIS) study group. Pediatr Infect Dis J 22:S55–S57PubMedGoogle Scholar
  15. 15.
    Manzoni P, Paes B, Resch B et al (2012) High risk for RSV bronchiolitis in late preterm’s and selected infants affected by rare disorders: a dilemma of specific prevention. Early Human Dev 88:S34–S41CrossRefGoogle Scholar
  16. 16.
    Speer ME, Fernandes CJ, Boron M et al (2008) Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J 27:559–561PubMedCrossRefGoogle Scholar
  17. 17.
    Robinson KA, Odelola OA, Saldanha IJ et al (2012) Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis (Review). The Cochrane Library 2:1–22Google Scholar
  18. 18.
    Prescott WA, Hutchinson DJ (2011) Respiratory syncytial virus prophylaxis in special populations: is it something worth considering in cystic fibrosis and immunosuppression? JPPT 16:77–86PubMedGoogle Scholar
  19. 19.
    Boeckh M, Berrey MM, Bowden RA et al (2001) Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. JID 184:350–354PubMedCrossRefGoogle Scholar
  20. 20.
    Kassis C, Champlin RE, Hachem RY et al (2010) Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab. Biol Blood Marrow Transplant 16:1265–1271PubMedCrossRefGoogle Scholar
  21. 21.
    De Fontbrune FS, Robin M, Porcher R et al (2007) Palivizumab treatment of respiratory syncytial virus infection after allogeneic hemopoietic stem cell transplantation. Clin Infect Dis 45:1019–1024PubMedCrossRefGoogle Scholar
  22. 22.
    Santos RP, Chao J, Nepo AG et al (2012) The use of intravenous palivizumab for treatment of persistent RSV infection in children with leukemia. Pediatrics 130:e1695–e1699PubMedCrossRefGoogle Scholar
  23. 23.
    Danziger-Isakov LA, Arslan D, Sweet S et al (2012) RSV prevention and treatment in pediatric lung transplant patients: a survey of current practices among the International Pediatric Transplant Collaborative. Pediatr Transpl 16:638–644CrossRefGoogle Scholar
  24. 24.
    Zhu Q, Patel NK, McAuliffe JM et al (2012) Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab. JID 205:635–638PubMedCrossRefGoogle Scholar
  25. 25.
    Fernandez P, Trenholme A, Abarca K et al (2010) A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr 10:38–51PubMedCrossRefGoogle Scholar
  26. 26.
    Carbonell-Estrany X, Simões EAF, Dagan R et al (2010) Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 125:e35–e51PubMedCrossRefGoogle Scholar
  27. 27.
    Feltes TF, Sondheimer HM, Tulloh RMR et al (2011) A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediat Res 70:186–191PubMedCrossRefGoogle Scholar
  28. 28.
    Mejías A and Ramilo O (2008) Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants. Biologics: Targets Ther 2:433–439Google Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations